1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance [TA263] Published date: 22 August 2012

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Related NICE guidance
  • 8 Review of guidance
  • Appendix A: Appraisal Committee members and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download

Guidance

  • Next

7 Related NICE guidance

7 Related NICE guidance

Published

  • Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer. NICE technology appraisal guidance 214 (2011).

  • Advanced breast cancer: diagnosis and management. NICE clinical guideline 81 (2009).

  • Gemcitabine for the treatment of metastatic breast cancer. NICE technology appraisal guidance 116 (2007).

  • National Institute for Health and Care Excellence (NICE)

  • Next